Talaris Therapeutics Inc (TALS) Stock
TALS is no longer traded. Talaris Therapeutics was delisted from the Nasdaq in October 2023.
Prices on this page are historical; the last trade was October 19, 2023 at $2.72.
Talaris Therapeutics stock price history
TALS final trading statistics
- Final close
- $2.72
- Final trading day
- Oct 19, 2023
- Market cap at delisting
- $116.44M
- Shares outstanding
- 42.81M
- Final 52-week range
- $0.89 – $3.29
- Avg. volume (final 3 mo.)
- 151,575
- All-time high (split-adj.)
- $175.76 · Jun 2021
- All-time low (split-adj.)
- $8.85 · Dec 2022
- Return since IPO
- -83.3%
- Beta
- 2.18
- Book value / share
- $34.88
- Price / book
- 0.08
Talaris Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$68.7M | -$6.55 |
| FY2021 | $0.00 | -$48.2M | -$2.38 |
| FY2020 | $0.00 | -$22.7M | -$0.16 |
| FY2019 | $0.00 | -$17.9M | -$0.76 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Talaris Therapeutics Inc
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc., in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
Talaris Therapeutics stock FAQ
What happened to Talaris Therapeutics stock?
Talaris Therapeutics stock was delisted from the Nasdaq. Its final close was $2.72 on October 19, 2023.
Is TALS stock still trading?
No. TALS was delisted from the Nasdaq in October 2023 and no longer trades on a U.S. exchange.
What was the last price of TALS stock?
TALS closed at $2.72 on its final trading day, October 19, 2023, for a market value of about $116.44M.
What were Talaris Therapeutics's revenue and earnings in its last full fiscal year?
Talaris Therapeutics reported revenue of $0.00 and net income of -$68.7M in fiscal 2022, its last full year as a public company.
When did Talaris Therapeutics go public?
Talaris Therapeutics Inc stock began trading on May 7, 2021.